Clearside Biomedical, Inc. Common Stock, also called Clearside Biomedical, is a clinical stage biopharmaceutical company, which engages in the development of drug therapies to treat blinding diseases of the eye. Read More Its pipeline includes Suprachoroidal CLS-TA, Suprachoroidal, Suprachoroidal CLS-TA, and gene therapy. The company was founded by Samir Kumar Patel, Vladimir Zarnitsyn, Mark Prausnitz, Daniel H. White, and Henry F. Edelhauser in May 2011 and is headquartered in Alpharetta, GA.